BioLife Solutions: The Whole Is Much More Than The Sum Of The Parts
The company enjoys strong secular tailwinds from a growing regenerative medicine market, gaining lots of new customers and seeing existing customers move through clinical phases.
Acquisitions have added significantly to the TAM and provided multiple leverage opportunities, especially in sales.
Gross margins have taken a hit from the acquisitions and dilution has been substantial.
While the shares are fully valued at the moment, the company appears to be an unstoppable juggernaut.